0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%
Last update at 2024-12-24T16:49:00Z
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
Thu 21 Nov 24, 12:00 AMIs AstraZeneca a Buy as It Eyes the Weight Loss Market?
Thu 14 Nov 24, 12:00 AM3 Magnificent Stocks Under $100 to Buy in November
Sun 03 Nov 24, 12:00 AM3 Rock-Solid Dividend Stocks You Can Buy and Hold Forever
Thu 31 Oct 24, 12:00 AMUK Stocks That May Be Trading Below Estimated Value
Mon 21 Oct 24, 06:03 AMWith 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing
Sun 20 Oct 24, 07:06 AMAstraZeneca (AZN): High-Growth UK Stock with Strong Pipeline
Thu 17 Oct 24, 05:59 PMThe Zacks Analyst Blog Highlights AstraZeneca, Accenture, AT&T and National Presto Industries
Thu 17 Oct 24, 12:15 PMThe best stocks to buy in the UK, according to Barclays
Thu 17 Oct 24, 11:27 AMTop Research Reports for AstraZeneca, Accenture & AT&T
Wed 16 Oct 24, 08:11 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 1993.00M |
| Minority interest | -5.00000M | -3.00000M | 16.00M | 1469.00M | 1576.00M |
| Net income | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Selling general administrative | 18955.00M | 15680.00M | 11693.00M | 8964.00M | 8479.00M |
| Selling and marketing expenses | 18955.00M | 15680.00M | 11693.00M | 11848.00M | 10362.00M |
| Gross profit | 31960.00M | 24980.00M | 21318.00M | 19463.00M | 17154.00M |
| Reconciled depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Ebit | 3757.00M | 1056.00M | 5162.00M | 2924.00M | 3412.00M |
| Ebitda | 9327.00M | 7565.00M | 8371.00M | 7016.00M | 7165.00M |
| Depreciation and amortization | 5570.00M | 6509.00M | 3209.00M | 4092.00M | 3753.00M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 3757.00M | 1056.00M | 5162.00M | 2924.00M | 3387.00M |
| Other operating expenses | 40594.00M | 36361.00M | 21455.00M | 21186.00M | 18703.00M |
| Interest expense | 1346.00M | 1300.00M | 1306.00M | 1432.00M | 1419.00M |
| Tax provision | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Interest income | 95.00M | 43.00M | 87.00M | 774.00M | 778.00M |
| Net interest income | -1251.00000M | -1257.00000M | -1219.00000M | -1237.00000M | -1228.00000M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | -792.00000M | -380.00000M | 772.00M | 321.00M | -57.00000M |
| Total revenue | 44351.00M | 37417.00M | 26617.00M | 24384.00M | 22090.00M |
| Total operating expenses | 28203.00M | 23924.00M | 16156.00M | 16265.00M | 13767.00M |
| Cost of revenue | 12391.00M | 12437.00M | 5299.00M | 4921.00M | 4936.00M |
| Total other income expense net | -1256.00000M | -1321.00000M | -1246.00000M | -1376.00000M | -1394.00000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 3293.00M | 115.00M | 3144.00M | 1227.00M | 2050.00M |
| Net income applicable to common shares | 3288.00M | 112.00M | 3196.00M | 1335.00M | 2155.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 101119.00M | 96483.00M | 105363.00M | 66729.00M | 61377.00M |
| Intangible assets | 38089.00M | 39307.00M | 42387.00M | 20947.00M | 20833.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 116.00M | 11489.00M | 105.00M | 7528.00M | 6152.00M |
| Total liab | 61953.00M | 59425.00M | 66076.00M | 51091.00M | 46781.00M |
| Total stockholder equity | 39143.00M | 37037.00M | 39268.00M | 15622.00M | 13127.00M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 21726.00M | 1711.00M | 1763.00M | 2136.00M | 2120.00M |
| Common stock | 388.00M | 387.00M | 387.00M | 328.00M | 328.00M |
| Capital stock | 388.00M | 387.00M | 387.00M | 328.00M | 328.00M |
| Retained earnings | 1502.00M | -574.00000M | 1710.00M | 5299.00M | 2812.00M |
| Other liab | - | 8499.00M | 13011.00M | 10491.00M | 10283.00M |
| Good will | 20048.00M | 19820.00M | 19997.00M | 11845.00M | 11668.00M |
| Other assets | - | 4172.00M | 5302.00M | 4284.00M | 3466.00M |
| Cash | 5840.00M | 6166.00M | 6329.00M | 7832.00M | 5369.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 30542.00M | 26293.00M | 22594.00M | 20307.00M | 18117.00M |
| Current deferred revenue | 149.00M | - | - | - | - |
| Net debt | 22782.00M | 23066.00M | 24452.00M | 12548.00M | 12858.00M |
| Short term debt | 5400.00M | 5542.00M | 1893.00M | 2386.00M | 2010.00M |
| Short long term debt | 5129.00M | 5314.00M | 1660.00M | 2194.00M | 1822.00M |
| Short long term debt total | 28622.00M | 29232.00M | 30781.00M | 20380.00M | 18227.00M |
| Other stockholder equity | 35636.00M | 37224.00M | 37171.00M | 9995.00M | 9987.00M |
| Property plant equipment | - | 9449.00M | 10171.00M | 8917.00M | 8335.00M |
| Total current assets | 25054.00M | 22593.00M | 26244.00M | 19544.00M | 15563.00M |
| Long term investments | - | - | - | - | 1512.00M |
| Net tangible assets | - | -22090.00000M | -23116.00000M | -17170.00000M | -19374.00000M |
| Short term investments | 20.00M | 239.00M | 69.00M | 160.00M | 849.00M |
| Net receivables | 13552.00M | 10521.00M | 10758.00M | 5651.00M | 5181.00M |
| Long term debt | 22365.00M | 22965.00M | 28134.00M | 17505.00M | 15730.00M |
| Inventory | 5424.00M | 4699.00M | 8983.00M | 4024.00M | 3193.00M |
| Accounts payable | 3267.00M | 19040.00M | 18938.00M | 15785.00M | 13987.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 23.00M | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 1617.00M | - | - | -8193.00000M | -7517.00000M |
| Additional paid in capital | 35341.00M | - | - | - | - |
| Common stock total equity | - | - | - | 328.00M | 328.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | 0.00000M | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 1051.00M | 1148.00M | 1066.00M | 1051.00M | 1650.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 76065.00M | 73890.00M | 79119.00M | 47185.00M | 45814.00M |
| Capital lease obligations | 1128.00M | 953.00M | 987.00M | 681.00M | 675.00M |
| Long term debt total | - | - | - | - | 16217.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2960.00000M | 605.00M | -285.00000M | 125.00M | 140.00M |
| Change to liabilities | 1165.00M | 1405.00M | 1721.00M | 868.00M | -103.00000M |
| Total cashflows from investing activities | -2960.00000M | -11058.00000M | -285.00000M | -657.00000M | 963.00M |
| Net borrowings | -1441.00000M | 7654.00M | 1440.00M | -1702.00000M | 1473.00M |
| Total cash from financing activities | -6823.00000M | 3649.00M | -2203.00000M | -1765.00000M | -2044.00000M |
| Change to operating activities | - | 2021.00M | 361.00M | 361.00M | 361.00M |
| Net income | 2501.00M | -265.00000M | 3916.00M | 1548.00M | 1993.00M |
| Change in cash | -55.00000M | -1508.00000M | 2323.00M | 552.00M | 1499.00M |
| Begin period cash flow | 6038.00M | 7546.00M | 5223.00M | 4671.00M | 3172.00M |
| End period cash flow | 5983.00M | 6038.00M | 7546.00M | 5223.00M | 4671.00M |
| Total cash from operating activities | 9808.00M | 5963.00M | 4799.00M | 2969.00M | 2618.00M |
| Issuance of capital stock | 29.00M | 29.00M | 30.00M | 3525.00M | 34.00M |
| Depreciation | 5480.00M | 6530.00M | 3149.00M | 3762.00M | 3753.00M |
| Other cashflows from investing activities | 60.00M | 54.00M | 87.00M | 274.00M | 193.00M |
| Dividends paid | -4364.00000M | -3856.00000M | -3572.00000M | -3592.00000M | 3484.00M |
| Change to inventory | 3941.00M | 1577.00M | -621.00000M | -316.00000M | -13.00000M |
| Change to account receivables | -1349.00000M | -961.00000M | -739.00000M | -898.00000M | -523.00000M |
| Sale purchase of stock | -920.00000M | 12413.00M | 3049.00M | 314.00M | 2971.00M |
| Other cashflows from financing activities | -297.00000M | -178.00000M | -101.00000M | 4.00M | -67.00000M |
| Change to netincome | -2491.00000M | -272.00000M | -1650.00000M | -816.00000M | -1709.00000M |
| Capital expenditures | 2571.00M | 2200.00M | 2606.00M | 2460.00M | 1371.00M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 3757.00M | 2021.00M | 361.00M | -346.00000M | -639.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -1930.00000M | -2323.00000M | -2627.00000M | -1995.00000M | -2489.00000M |
| Free cash flow | 7237.00M | 3763.00M | 2193.00M | 509.00M | 1247.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AZN AstraZeneca PLC ADR |
-0.235 0.35% | 66.39 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
| LLY Eli Lilly and Company |
-0.97 0.12% | 795.31 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
0.07 0.05% | 145.34 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
0.86 0.48% | 179.25 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
0.03 0.03% | 99.39 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
| Name | Title | Year Born |
|---|---|---|
| Mr. Pascal Soriot D.V.M., M.B.A. | CEO & Exec. Director | 1959 |
| Dr. Aradhana Sarin M.D. | CFO & Exec. Director | 1975 |
| Mr. Marc Dunoyer | CEO of Alexion & Chief Strategy Officer | 1952 |
| Ms. Pam P. Cheng | EVP of Operations & Information Technology and Member of External Sustainability Advisory Board | 1971 |
| Mr. Chris Sheldon | Head of Investor Relations | NA |
| Mr. Jeffrey Pott | Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board | NA |
| Ms. Katarina Ageborg | EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board | NA |
| Gonzalo Vina | Head of Global Media Relations | NA |
| Dr. Menelas Pangalos Ph.D. | EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board | 1967 |
| Dr. Ruud Dobber Ph.D. | Exec. Vice-Pres of BioPharmaceuticals Bus. Unit | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...